Skip to content

Validation of homoeopathic drugs for migraine

Validation of commonly used homoeopathic drugs for migraine: A prospective observational study

Status
Recruiting
Phases
Phase 3
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/014140
Enrollment
200
Registered
2018-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Migraine

Interventions

Sponsors

Central Council for Research in Homoeopathy New Delhi Ministry of AYUSH Government of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • At least 5 attacks of recurrent headache disorder fulfilling the following diagnostic criteria: A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) C. Headache has at least two of the following characteristics: 1. unilateral location 2. pulsating quality 3. moderate or severe pain intensity 4. aggravation by or causing avoidance of routine physical activity (e.g, walking or climbing stairs) D. During headache at least one of the following: 1. nausea and/or vomiting 2. photophobia and phonophobia E. Not attributed to another disorder • HIT-6 score > 50

Exclusion criteria

Exclusion criteria: 1. Diagnosed cases of sinusitis, cluster or tension headache, or any other ailment known to be closely associated with recurrent headache. 2. Pregnant or lactating women 3. Patients using regular migraine preventative medicines. 4. Patients with uncontrolled hypertension and diabetes. 5. Patient uses benzodiazepines or hormonal preparations. 6. Patients who abused stimulants or had an illness that made the practical participation in the trial difficult. 7. On allopathic drugs, other than for hypertension or diabetes mellitus 8. Other ongoing treatment which is likely to interfere with the course of this treatment.

Design outcomes

Primary

MeasureTime frame
To observe the change in Headache Impact Test (Hit-6) score at the end of 1 year of treatment.Timepoint: Baseline, 1 year

Secondary

MeasureTime frame
To observe the change in Quality of Life (WHO-QoL) at the end of 1 year of treatment.Timepoint: Baseline, 1 year

Countries

India

Contacts

Public ContactDr R K Manchanda

Central Council for Research in Homoeopathy

anilnaman@rediffmail.com011-28524266

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026